This article first appeared on GuruFocus.

MariMed Inc (MRMD) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $42.40 million, and the earnings are expected to come in at -$0.01 per share. The full year 2025's revenue is expected to be $163.80 million and the earnings are expected to be -$0.03 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 8 Warning Signs with MRMD.

Is MRMD fairly valued? Test your thesis with our free DCF calculator.

Over the past 90 days, revenue estimates for MariMed Inc (MRMD) have declined from $166.03 million to $163.80 million for the full year 2025, while they have increased from $185.03 million to $185.70 million for 2026. Earnings estimates have improved, rising from -$0.04 per share to -$0.03 per share for 2025, and from -$0.02 per share to -$0.01 per share for 2026.

In the previous quarter ending on June 30, 2025, MariMed Inc's (MRMD) actual revenue was $39.61 million, which missed analysts' revenue expectations of $40.93 million by -3.23%. MariMed Inc's (MRMD) actual earnings were $0 per share, which beat analysts' earnings expectations of -$0.01 per share by 100%. After releasing the results, MariMed Inc (MRMD) was down by -11.47% in one day.

Based on the one-year price targets offered by 2 analysts, the average target price for MariMed Inc (MRMD) is $0.23, with a high estimate of $0.25 and a low estimate of $0.20. The average target implies an upside of 116.35% from the current price of $0.10.

Based on GuruFocus estimates, the estimated GF Value for MariMed Inc (MRMD) in one year is $0.33, suggesting an upside of 217.31% from the current price of $0.10.

Based on the consensus recommendation from 3 brokerage firms, MariMed Inc's (MRMD) average brokerage recommendation is currently 2.0, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.